Crispr Therapeutics shares tumble after significant earnings miss
Fair Isaac and Company Inc. (NYSE:FICO) stock has reached a new 52-week low, closing at $1,470.97. The company maintains strong fundamentals with impressive gross profit margins of 81% and a healthy current ratio of 2.11, according to InvestingPro data. This milestone reflects a challenging year for the company, which has seen its stock price decrease by 3.24% over the past 12 months. Despite the decline, which underscores ongoing pressures within the financial technology sector, FICO has demonstrated resilient performance with 14.7% revenue growth over the last twelve months. Based on InvestingPro’s Fair Value analysis, the stock appears overvalued at current levels. Despite this setback, Fair Isaac continues to play a significant role in credit scoring and analytics, navigating the complexities of a rapidly evolving financial landscape. Get access to 14 additional exclusive ProTips and comprehensive analysis in the FICO Pro Research Report, available on InvestingPro.
In other recent news, Fair Isaac Corporation reported its Q3 2025 earnings, exceeding analysts’ expectations. The company achieved a non-GAAP earnings per share of $8.57, surpassing the projected $7.68. Additionally, Fair Isaac’s revenue reached $536 million, which was above the anticipated $515.33 million. These results indicate a strong performance for the quarter. While the stock price saw some fluctuation, the focus remains on the company’s financial achievements. There have been no recent mergers or acquisitions reported for Fair Isaac. Analyst firms have not recently provided any updates regarding upgrades or downgrades for the company. These developments highlight Fair Isaac’s solid financial standing in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.